23 juillet, 2012by Mario22 July 201222 July 2012Alethia Biothérapeutiques reçoit un avis d’acceptation d’un brevet concernant l’utilisation d’anticorps anti-Siglec-15 Alethia 120723 FR Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Name * Email * Website Comment * Save my name, email, and website in this browser for the next time I comment.